financial information

U.S. Stock Futures Dip as ​AI⁤ Concerns Weigh on Investor Sentiment

New York – U.S. stock index futures‌ declined in pre-market trading⁤ Friday, as growing skepticism surrounding the artificial intelligence (AI) boom dampened risk appetite. The⁣ downturn comes ahead of a day of economic data releases and federal Reserve speeches.

BOSS Direct Recruitment reported third-quarter revenue of 2.16 billion yuan, a 13.2% year-over-year increase, driven by online recruitment‌ services to corporate ‍customers, which generated 2.15 billion yuan in revenue.the company’s paying‌ enterprise customer base reached 6.8 million as of September ​30, 2025, a​ 13.3% increase year-over-year.

iQiyi released its third-quarter 2025 ⁤financial results, reporting total revenue of ​6.68 billion yuan,down 8% year-on-year. The company⁣ recorded an adjusted ‌net ⁢loss of 150 million yuan, compared to a net ​profit of 229.4 million yuan in‌ the same period of 2024.Net loss attributable to iQiyi‍ was 148.2 million yuan, versus‌ a net profit of 479.8 million yuan in the prior ⁢year.

Key Economic Events Scheduled for November 18th (Beijing Time):

* ‍ 21:55: U.S. Red Book commercial retail sales annual rate for the week to November 14.
* 22:00: Final U.S. durable goods orders monthly rate for August.
* 23:00: U.S. November NAHB housing market index &⁤ U.S. August factory orders monthly rate.
* ⁢ 23:30: Speech by Federal Reserve​ Board Governor Barr.

Scheduled for November 19th:

* 00:00: remarks from Richmond Fed President Barkin on the⁤ economic outlook.
* 04:00: U.S. ⁤net ⁤international capital inflows for August.
* 05:30: API⁣ crude oil inventories for the week to november​ 14.

(Source: Financial⁣ Associated Press)

Disclaimer: Oriental Fortune publishes this content to disseminate facts.It does not reflect the views​ of this site and does not constitute investment‍ advice. Operate at yoru own risk.

China‘s Financial ⁢Data for First 10 ‍Months Signals Economic Recovery & diversified Financing

Recent financial data from the People’s Bank of China indicates a strengthening economic landscape, ⁤characterized by increased corporate activity, recovering consumer demand, ⁢and a shift ​towards more diversified financing methods. The data covers the first ten months ⁤of the year and points to ‍a moderately loose monetary policy supporting growth.

Narrow⁣ money supply (M1) saw a year-on-year increase of 6.2%. Notably, the gap between growth in ⁣M2 (broad money supply) and M1 has narrowed substantially compared to the same period last year, suggesting increased velocity of money.

According to Zhang Jun, chief ⁣Economist at Milky way Securities, thes figures reflect robust corporate production and operations alongside a resurgence in​ personal investment and consumption. He emphasized that lowering the interest burden on businesses and individuals ⁤is‍ crucial ‍for unlocking financing needs and fueling ⁤economic⁣ activity.

Supporting this, the weighted average interest rate on new corporate loans (local and foreign currencies) in ⁤october fell to 3.1%, a decrease of 40 basis points year-on-year. New personal housing loan rates also saw a reduction,⁢ dropping to 3.1%, down 8 basis points from the previous year. Zhang Jun ⁤attributed these declines to the ​People’s Bank⁢ of china’s efforts⁤ to broaden ​countercyclical ‌adjustment policies, improve market-based interest rate controls, ‍and promote transparency in corporate loan financing costs. Further reductions in personal interest burdens are expected with the implementation of fiscal discounts on personal consumption loans.

Beyond customary lending, bond financing has experienced substantial growth. Cumulative social financing increased by 30.9 trillion⁣ yuan in the first ten months of the year. Net corporate ‍bond financing reached 1.82 ​trillion yuan, an increase of 136.1 billion yuan year-on-year, while net government bond financing totaled 11.95 trillion yuan, a significant rise of 3.72 trillion​ yuan.

This shift is reflected in the composition of new social financing, with government and corporate⁢ bonds ‌now ‌accounting for approximately 45% of the total. Zhang Xu, chief ⁣Fixed Income Analyst at Everbright Securities, highlighted this trend as a sign of ⁢a maturing financial system.⁣ ​ Companies are increasingly diversifying their financing channels, moving⁢ beyond reliance on bank loans to incorporate bonds, stocks, and other market-oriented‍ methods.

Looking ahead, the People’s Bank of China intends to maintain a moderately loose monetary policy ‌and ensure relatively loose social financing conditions. ‍ The bank will prioritize utilizing monetary and credit ⁤policies​ to support ‍major national strategies, key economic areas, and address existing weaknesses. Efforts will continue to refine market-oriented interest rate mechanisms to further reduce ​overall social⁤ financing costs.

(Source: Xinhua News Agency)

Original title: Financial Focus丨Where will the ‌nearly 15 trillion yuan in new loans be invested? –A look at ‍my country’s financial data for the first 10 months

Disclaimer: Oriental Fortune publishes this content to disseminate more ⁣details. It has nothing to do with the position of this site and dose ⁣not constitute⁢ investment advice. Operate accordingly at your own risk.

Foreign Pharmaceutical ⁣& Device Companies Deepen Engagement⁣ in China: Local Innovation & Increased ⁣Investment Highlight CIIE

The ⁤recent China ⁣International Import Expo (CIIE) underscored a growing trend: foreign pharmaceutical and ​medical ‌device companies are increasingly focusing on localized innovation and expanding their investment within⁣ China. This shift ⁣aims to ⁣better serve the ‍Chinese market,accelerate access to new therapies,and contribute to the growth of the⁢ nation’s ‍healthcare industry.

A key theme⁤ highlighted ⁣at the CIIE was the commitment‍ to utilizing the event as a platform for⁣ introducing breakthrough therapies in critical areas like oncology, ‌immunity, neuroscience, and cardiopulmonary diseases. The goal is to streamline the process of drug⁣ registration and launch, effectively bridging the gap between research & progress ‌and patient access, ultimately meeting the evolving health needs of the Chinese population.

Fosun Pharma ⁤ exemplified this ‍trend, demonstrating a transition from ⁤simply “introducing”⁢ foreign technologies to actively “localizing” ​them. ⁤ The company showcased ‍the Marie vertical ⁣particle therapy system, ⁤a compact ‍alternative to traditional radiotherapy.Moreover, ‍their JediVision pulmonary nodule AI-AR navigation system, combining domestically developed software and hardware,⁢ is⁢ already in clinical use⁣ at leading hospitals nationwide.

Fosun⁢ Pharma is ​also⁤ making notable strides in cell therapy. yikaida® (Akilenza Injection), China’s first⁤ CAR-T product, has successfully⁢ treated⁢ over 1,000 lymphoma patients, with accessibility improved through collaborations with medical ⁣and commercial insurance providers. The company announced⁤ in ⁢september 2025, the State Food and ⁣Drug Administration accepted⁢ the ⁤drug registration⁣ request for their second CAR-T product, brigiolenza ⁤Injection (FKC889), intended for adult patients with⁣ relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Beyond therapies,​ Fosun Pharma is actively localizing‌ manufacturing. The ​da Vinci‍ xi surgical robot is ⁢now being domestically ⁢produced, with expectations that over 70% ⁤of ⁤units sold in China by the end of ⁤2025 will be manufactured locally. ​The‌ opening of Intuitive Fosun’s ⁤headquarters industrial base‌ in Pudong, ⁣Shanghai, represents Intuitive⁢ medical’s largest​ integrated ‌R&D and production⁢ center in the‌ Asia-Pacific‍ region, signifying a‍ move ⁤”from exhibitor to investor.”

(Source: Guangzhou Daily New ⁢Flower⁢ City)

Disclaimer: Oriental Fortune publishes this content to disseminate more details.‍ It‌ has ‍nothing to do with the position⁢ of this site and does not constitute investment advice. Operate accordingly at your own risk.

Nissan to sell Headquarters, Volkswagen to Develop‍ In-House chips

Nissan Motor Co. is planning to​ sell its⁣ Yokohama headquarters building, according to reports on November ⁢6th. The move is⁢ part of a broader restructuring effort by the automaker.

Separately, Volkswagen Group​ is accelerating plans to ‌develop its own automotive ⁢chips, aiming ⁤for greater control over its supply chain and technological independence. The initiative reflects a growing‌ industry⁤ trend toward in-house chip development amid global semiconductor shortages.

These developments were highlighted in the ‌”Automotive⁢ Morning participation” report ⁢from Oriental Fortune Network on November 6th.⁢

additionally, Li Auto is reportedly investing in battery technology companies to bolster its competitiveness in ⁣the ⁤electric vehicle market ‌and support the development⁣ of EV charging infrastructure. This move is expected to attract investor attention to the battery sector and boost confidence in new energy markets.

Zhuanfeng Intelligent Technology (Shenzhen) Co.,Ltd., a⁢ new intelligent technology company, was recently established wiht a registered capital of 28 ⁤million yuan. The company is jointly owned by Pony.ai subsidiaries, Toyota Motor (China) Investment Co., Ltd., and GAC Toyota Motor Co., Ltd.,and will focus on intelligent instrumentation manufacturing,auto⁣ parts sales,and charging pile ⁣sales,including centralized fast charging stations. This venture signifies a deepened collaboration between Pony.ai and⁤ Toyota ​in the smart car sector.

(Source: Daily Economic News)

Disclaimer: Oriental Fortune publishes this ‌content ‍to disseminate more data.It has nothing⁣ to ‍do with the position of this site and does not constitute investment advice.Operate accordingly at your own risk.

Robot Concept Stocks Surge as Xpeng‘s He Xiaopeng Denies “Human inside”⁢ Rumor

BEIJING – Shares in companies linked to the humanoid robot sector rose ​sharply on November 6th, fueled by industry optimism and a direct response from ⁢Xpeng founder He Xiaopeng to circulating rumors about his company’s “IRON” robot. The gains come as analysts predict⁢ a​ shift from early-stage advancement to commercialization within‍ the industry.

According to ⁣a research report from CITIC Construction Investment, the ⁢humanoid​ robot industry ‍is accelerating from a “0~1” phase – initial concept and development – to a “1” ⁢phase, signifying‍ increasing commercial viability. The report suggests the sector is ⁣poised to ​enter a period ‍of consolidation, favoring established players. This transition is expected to be bolstered by continued policy support, investment, and confirmed orders.

The rally appears partly triggered by developments surrounding Xpeng Robotics. He Xiaopeng personally refuted claims that the IRON robot contains ‍a human operator, stating mass production of high-end models is anticipated by the ⁤end of next year.

Leading the gains were Sanhua Smart Control, up 7.35%, followed by Johnson ​Electric Holdings,⁢ rising 6.68%. Aberdeen Robot⁣ increased by 3.64%, while‍ Jinli‍ Permanent Magnet and Sagitar Juchuang saw gains of 3.92% and 2.79% respectively. Best​ choice ⁣closed up 1.66%.

Analysts at securities firms believe the industry is experiencing a period of intense catalytic activity, with⁤ the integration of humanoid robots into industrial applications becoming increasingly likely both domestically and ⁢internationally.

(Source: Daily Economic News)

Disclaimer: Oriental Fortune ⁢publishes this content to ​disseminate facts. It does not‌ reflect the ⁢views of this site and does ⁢not‌ constitute investment advice.Operate at your own risk.

CSPC Executive Director Fined 5 Million Yuan for Insider Trading

Shenzhen, China – Pan Weidong, an executive director⁤ of CSPC Pharmaceutical Group, has been fined 5 million yuan (approximately $700,000 USD) by securities regulators for ⁢insider trading involving nearly 100 million yuan (approximately $14 million USD) in stocks, according to a report from Read Chuang Finance via Oriental Fortune Network.

The⁣ penalty stems from trading activity related to a restructuring ⁤transaction ⁢announced on January 10, 2024, which was ultimately terminated on April 28, 2025.⁣ CSPC Innovation (formerly ⁢CSPC ⁢Xinnuovi Pharmaceutical Co., ⁤ltd.) stated the termination was due⁢ to a comprehensive assessment of the pharmaceutical industry ⁣environment and capital market conditions,‍ reached through​ interaction and negotiation⁤ with relevant parties. The company maintained there was no breach​ of contract liability.

Pan Weidong ‍resigned as chairman of CSPC Innovation on September 23,2024. ‍He retains the right to appeal ⁤the decision through administrative reconsideration or litigation.

As of‌ the date of the proclamation, ⁢CSPC Pharmaceutical Group, through its subsidiary CSPC Ouyi Pharmaceutical Co., Ltd.,‌ held ‍1.037 billion shares of ⁢CSPC Innovation, ‍representing approximately 74.66% of the company’s total ⁢share‍ capital. ⁤This includes an additional 11.5872 million shares, accounting for⁢ roughly ⁢0.23% of the ⁣total.

CSPC Pharmaceutical Group stated that the penalties‌ are not expected to negatively​ impact the group’s overall business⁢ operations,which remain normal.

CSPC⁢ Innovation, established in 2006 as CSPC Xinnuovi Pharmaceutical Co., Ltd., listed on the⁤ A-share GEM in 2019 and officially changed its name in November 2023. The company reported ⁣operating income of 1.59 billion yuan in the first ⁤three quarters of the current year, a 7.7% year-on-year increase. ⁤However, it also reported a net loss attributable to the parent company of 24.05‌ million yuan,a 117.3% year-on-year‌ decrease, and⁣ a net loss after non-attribution to the parent company of 64.82 million yuan, a 147.4% year-on-year decrease.

Disclaimer: Oriental Fortune publishes⁤ this content to disseminate more information. It has nothing to do with the position of this site and does not constitute investment advice. Operate accordingly​ at your ‍own risk.